Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020

Genentech announced that new multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) data will be presented at MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) – European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting, from September 11–13, 2020.

“While conditions of the nervous system are some of the most complex to understand and treat, we are committed to following the science to reduce relapses in NMOSD and slow and eventually stop disease progression in MS,” Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development, said in a company news release. “From the success of our first-in-class B cell MS therapy Ocrevus, we are poised to continue advancing the science in MS with our new investigational BTK inhibitor fenebrutinib, and in NMOSD with the recent FDA approval of Enspryng.”

Neuromyelitis Optica Spectrum Disorder (NMOSD)

New data show Enspryng lowered relapse severity in people with NMOSD in double-blind periods of SAkura phase 3 studies. Pooled data from SAkura open-label extension (OLE) studies also showed Enspryng significantly reduced risk of relapse, further reinforcing the findings from the double-blind period. Preventing relapses, the most severe of which cause cumulative, irreversible neurological damage and disability, is the primary goal for NMOSD disease management.

On August 14, Enspryng was approved by the FDA as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive NMOSD, a rare disabling neurological disorder often mistaken for MS. Enspryng can be self-administered every four weeks by a person living with NMOSD or a caregiver, after an initial loading dose and following training by a healthcare provider.

Until recently, people living with NMOSD did not have medicines specifically tested and designed to treat the condition. Many people with NMOSD remain misdiagnosed and untreated.

New data from the double-blind and OLE trials continue to build on one of the largest pivotal clinical trial programs undertaken for this rare neurological disease, further demonstrating Enspryng’s sustained efficacy and favorable safety profile in adults with NMOSD.

Follow Genentech on Twitter via @Genentech and keep up to date with MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting news and updates by using the hashtag #MSVIRTUAL2020.

A full list of Genentech presentations can be found at: https://cslide.ctimeetingtech.com/msdc2020/attendee/confcal/session